1.	Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 04-126, R21CA115043, P30CA006516, CDR0000456445, DFCI-04126, NCT00301093
2.	Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation Phase: Phase I Type: Treatment Status: Temporarily closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 08-160, NCT00809250
3.	Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: J05115, CDR0000491987, P30CA006973, JHOC-J05115, NCT00361296